Sign in to view content

Prognostic Value of Subretinal Hyperreflective Material

Russell Pokroy, MD

Video
Published 2017

Related

Pharmacokinetic Profile of the Port Delivery System with Ranibizumab (PDS) in the Phase 3 Archway Trial
Peter A. Campochiaro, MD
Updates from the Field
2021
Should We Ever Consider Stopping Treatment for Neovascular AMD?
Rahul N. Khurana, MD, FASRS
Updates from the Field
2020
Anti-VEGF treatment switch in DME and nAMD: a comparison of aflibercept versus ranibizumab after a single-dose switch
Estephania Feria, MD
On Demand Cases, Courses, and Papers
2019

Category: AMD-Neovascular

See more